Design, Synthesis, and Structure–Activity Relationship of N-Aryl-N′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design, Synthesis, and Structure–Activity Relationship of N-Aryl-N′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 11, Pages 7371-7389
Publisher
American Chemical Society (ACS)
Online
2021-05-25
DOI
10.1021/acs.jmedchem.0c02266
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TLR2 Agonistic Small Molecules: Detailed Structure–Activity Relationship, Applications, and Future Prospects
- (2020) Arshpreet Kaur et al. JOURNAL OF MEDICINAL CHEMISTRY
- TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes
- (2019) Xiaohong Cen et al. Advanced Science
- Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim
- (2019) Lijing Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis of urea analogues bearing N-alkyl-N'-(thiophen-2-yl) scaffold and evaluation of their innate immune response to toll-like receptors
- (2019) Zhipeng Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
- (2018) Si-si Wang et al. Cellular & Molecular Immunology
- Structure-based discovery of a specific TLR1–TLR2 small molecule agonist from the ZINC drug library database
- (2018) Zhipeng Chen et al. CHEMICAL COMMUNICATIONS
- Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti–PD-L1 to eliminate melanoma in mice
- (2018) Ying Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists
- (2018) Matthew D. Morin et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Identification of Human Toll-like Receptor 2-Agonistic Activity in Dihydropyridine–Quinolone Carboxamides
- (2018) Ziwei Hu et al. ACS Medicinal Chemistry Letters
- Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication
- (2018) Gijs G. Zom et al. Journal for ImmunoTherapy of Cancer
- Naive CD4+T Cells Carrying a TLR2 Agonist Overcome TGF-β–Mediated Tumor Immune Evasion
- (2017) Mohsen Ibrahim et al. JOURNAL OF IMMUNOLOGY
- Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells
- (2017) Hiroaki Shime et al. OncoImmunology
- Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia
- (2015) Nina Rolf et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Discovery of small molecule inhibitors of MyD88-dependent signaling pathways using a computational screen
- (2015) Mark A. Olson et al. Scientific Reports
- A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells
- (2015) Melissa Santone et al. Human Vaccines & Immunotherapeutics
- Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
- (2015) K. Cheng et al. Science Advances
- Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
- (2014) S.-K. Lee et al. CLINICAL CANCER RESEARCH
- Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice
- (2014) Yufei Zhang et al. CLINICAL IMMUNOLOGY
- The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses
- (2014) Brendon Y Chua et al. IMMUNOLOGY AND CELL BIOLOGY
- Human Toll-Like Receptor 8-Selective Agonistic Activities in 1-Alkyl-1H-benzimidazol-2-amines
- (2014) Mallesh Beesu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand-Peptide Conjugates
- (2014) G. G. Zom et al. Cancer Immunology Research
- Targeting Toll-like receptors with small molecule agents
- (2013) Xiaohui Wang et al. CHEMICAL SOCIETY REVIEWS
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Discovery of Small-Molecule Inhibitors of the TLR1/TLR2 Complex
- (2012) Kui Cheng et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Evaluation and Discovery of Novel Synthetic Chalcone Derivatives as Anti-Inflammatory Agents
- (2011) Jianzhang Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small-Molecule Inhibitors of the TLR3/dsRNA Complex
- (2011) Kui Cheng et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Intracellular Toll-like Receptors
- (2010) Amanda L. Blasius et al. IMMUNITY
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Toll-like receptor signaling in cell proliferation and survival
- (2009) Xinyan Li et al. CYTOKINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started